[InnoCare: The phase II clinical trial of the innovative drug ICP-488 achieved positive results] Jinshi Data reported on October 9 that InnoCare announced in the evening that the company’s innovative drug ICP-488 has shown positive results in patients with moderate to severe plaque psoriasis. Positive clinical trial results were obtained in a phase II randomized, double-blind, placebo-controlled study conducted in China. Study results showed that patients treated with 6 mg and 9 mg (once daily) ICP-488 had significant improvements in PASI75 at week 12 compared with patients receiving placebo. In addition, the proportion of patients who received ICP-488 treatment who achieved PASI90, PASI100 and static clinician global assessment (sPGA) 0/1 (i.e. complete or basically clear skin lesions) was significantly higher than that in the placebo group. (Reprinted from: Jinshi Data)